Abstract

Bacillary dysentery caused by Shigella is one of the most important factors characterized by acute diarrhea in developed and developing countries. Probiotics reduce intensity risk of intestinal diseases. This study evaluates influences of Lactobacillus casei and Lactobacillus fermentum metabolites against Shigella Flexneri isolated from clinical samples. Antibiotic resistance of clinical samples of Shigella and Lactobacillus casei and Lactobacillus fermentum were assessed using agar-based minimal inhibitory concentration assay. 34 clinical samples of Shigella flexneri from patients were assayed for the antimicrobial activity of Lactobacillus metabolites using broth micro dilution method, minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC). Standard bacterial growth curves were drawn up by performance of turbidometric measurements to compare antibacterial effects of Lactobacilli metabolites against clinical samples. Antibiogram was carried out for 34 samples with positive culture. Antibiotic resistant bacteria were revealed for tetracycline, streptomycin and tobramycin. In this study chloramphenicol, tobramycin and amikacin resistance in Lactobacillus casei were detected and Lactobacillus fermentum was resistant to ceftazidime, tobramycin and amikacin. MIC and MBC of Lactobacillus casei against Shigella flexneri was 62.5 and 62.5. MIC and MBC of Lactobacillus fermentum against Shigella flexneri were 62.5, 15.6 respectively. It shows that Lactobacillus casei and Lactobacillus fermentum can be used as probiotic candidate against Shigella flexneri.